145 related articles for article (PubMed ID: 22862176)
1. Ovarian cancer stem cells.
Zeimet AG; Reimer D; Sopper S; Boesch M; Martowicz A; Roessler J; Wiedemair AM; Rumpold H; Untergasser G; Concin N; Hofstetter G; Muller-Holzner E; Fiegl H; Marth C; Wolf D; Pesta M; Hatina J
Neoplasma; 2012; 59(6):747-55. PubMed ID: 22862176
[TBL] [Abstract][Full Text] [Related]
2. The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells.
Sun Y; Li T; Ma K; Tian Z; Zhu Y; Chen F; Hu G
Cancer Invest; 2009 Nov; 27(9):891-7. PubMed ID: 19832035
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian cancer stem cells.
Bapat SA
Reproduction; 2010 Jul; 140(1):33-41. PubMed ID: 20368192
[TBL] [Abstract][Full Text] [Related]
4. Isolation of cancer stem-like cells from a side population of a human glioblastoma cell line, SK-MG-1.
Fukaya R; Ohta S; Yamaguchi M; Fujii H; Kawakami Y; Kawase T; Toda M
Cancer Lett; 2010 May; 291(2):150-7. PubMed ID: 19913993
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.
Luo L; Zeng J; Liang B; Zhao Z; Sun L; Cao D; Yang J; Shen K
Exp Mol Pathol; 2011 Oct; 91(2):596-602. PubMed ID: 21787767
[TBL] [Abstract][Full Text] [Related]
8. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
9. Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis.
Sang XB; Sun KX; Wang LL; Chen S; Wu DD; Zong ZH; Zhao Y
Oncol Rep; 2016 Dec; 36(6):3267-3274. PubMed ID: 27748937
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
11. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.
Cannistra SA; Kansas GS; Niloff J; DeFranzo B; Kim Y; Ottensmeier C
Cancer Res; 1993 Aug; 53(16):3830-8. PubMed ID: 8339295
[TBL] [Abstract][Full Text] [Related]
12. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme.
Broadley KW; Hunn MK; Farrand KJ; Price KM; Grasso C; Miller RJ; Hermans IF; McConnell MJ
Stem Cells; 2011 Mar; 29(3):452-61. PubMed ID: 21425408
[TBL] [Abstract][Full Text] [Related]
13. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
14. Establishment of human ovarian serous carcinomas cell lines in serum free media.
Pan Z; Hooley J; Smith DH; Young P; Roberts PE; Mather JP
Methods; 2012 Mar; 56(3):432-9. PubMed ID: 22445873
[TBL] [Abstract][Full Text] [Related]
15. Tumor initiating cancer stem cells from human breast cancer cell lines.
Han JS; Crowe DL
Int J Oncol; 2009 May; 34(5):1449-53. PubMed ID: 19360358
[TBL] [Abstract][Full Text] [Related]
16. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral heterogeneity in the self-renewal and tumorigenic differentiation of ovarian cancer.
Abelson S; Shamai Y; Berger L; Shouval R; Skorecki K; Tzukerman M
Stem Cells; 2012 Mar; 30(3):415-24. PubMed ID: 22267284
[TBL] [Abstract][Full Text] [Related]
18. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.
Komuro H; Saihara R; Shinya M; Takita J; Kaneko S; Kaneko M; Hayashi Y
J Pediatr Surg; 2007 Dec; 42(12):2040-5. PubMed ID: 18082704
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the stem cell phenotypes of C6 cells under different culture conditions.
Zhang SJ; Ye F; Xie RF; Hu F; Wang BF; Wan F; Guo DS; Lei T
Chin Med J (Engl); 2011 Oct; 124(19):3118-26. PubMed ID: 22040566
[TBL] [Abstract][Full Text] [Related]
20. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D
Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
